Roy Jacobs & Associates Announces That a Class Action Has Been Filed Against KV Pharmaceutical Company Alleging Securities Law Violations

Roy Jacobs & Associates announces that a class action has been commenced on behalf of shareholders who acquired KV Pharmaceutical Company ("KV" or the "Company") Class A Common Stock (NYSE: KV-A), Class B Common Stock (NYSE: KV-B) and 7% cumulative convertible Preferred Stock (Symbol: KVPHP or CUSIP: 482740305) securities during the period commencing February 15, 2008 and through November 12, 2008 (the "Class Period").

For further information, please contact Roy L. Jacobs, Esq. toll-free at 1-888-884-4490 or by e-mail to rjacobs@jacobsclasslaw.com.

The Complaint alleges that KV and certain officers and directors violated the securities laws by failing to timely disclose problems concerning the manufacturing and distribution of certain pharmaceutical products. On November 13, 2008, it was revealed that KV would be unable to file its Form 10-Q for the quarter ended September 30, 2008 due to a continuing investigation by the Company’s Audit Committee into allegations of management misconduct concerning the recall of the Company’s drug products. As a result of the disclosure of this material adverse news, KV’s common stock fell from $14.26 per share to $5.90 per share – a drop of nearly 59%. Thereafter, on December 5, 2008 the Company announced that the Board of Directors had terminated the employment agreement of the Company’s chairman and chief executive officer, Marc Hermelin, for cause.

If you bought KV shares during the Class Period, from February 15, 2008 through November 12, 2008, and suffered a loss (whether or not you have sold your shares) and you are interested in discussing your rights free of charge, please contact Roy L. Jacobs. Mr. Jacobs will be glad to personally speak with you.

All motions for appointment as Lead Plaintiff must be filed by February 2, 2009.